Key Takeaways
- Amferia expands its animal health footprint into the Netherlands, Belgium, and Luxembourg through a partnership with Grovet BV.
- The company’s peptide-based hydrogel wound dressing targets antibiotic-resistant bacteria without harming surrounding tissue.
- The agreement builds on a milestone year for Amferia, including European product launches and continued progress toward U.S. regulatory approval.
An innovative wound care technology developed by Swedish medtech company Amferia is set to reach veterinarians in the Benelux region following a new distribution agreement with Grovet BV, a major animal health supplier operating in the Netherlands, Belgium, and Luxembourg.
The partnership is expected to make Amferia’s AMP Wound Dressing commercially available in the region as early as spring 2026. According to the company, the product has demonstrated significantly faster wound healing compared with conventional dressings in European research studies.
Addressing Antibiotic-Resistant Infections
A central feature of Amferia’s technology is its approach to antimicrobial resistance. Rather than relying on traditional antibiotics, the wound dressing uses antimicrobial peptides that attract bacteria through electrostatic charge and physically disrupt bacterial cell membranes. This mechanism allows the dressing to remain effective even against strains that have developed resistance to antibiotics.
Amferia’s proprietary hydrogel platform encases the peptides in a solid protective matrix, shielding them from enzymatic degradation while leaving their bacteria-killing structures exposed. Research cited by the company indicates that combining the hydrogel with antibiotics can amplify antibiotic effectiveness by up to 64 times.
Expanding Amferia’s Veterinary Presence
The Grovet agreement follows a milestone period for Amferia, which recently launched Europe’s first veterinary wound dressing based on antimicrobial peptides and continues to advance regulatory efforts for human wound care applications in the United States.
Grovet’s Head of Business Development, Chris Dujardin, said the company views the technology as a meaningful contribution to efforts to combat antibiotic resistance in animal health, with a Benelux launch planned in the near term.
Information sourced from the company’s press release.
